Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Prime Medicine

Main focus: Prime editing for the treatment of genetic diseases

Company stage: Pre-clinical

Diseases: Undisclosed

Genome editing tool: Prime editing

Funding stage: Private

Location: Cambridge, MA, USA


Gene editing partnerships: Beam Therapeutics

Prime Medicine is a start-up company that focuses on prime editing. Prime editing is a novel CRISPR-derived gene-editing technology, which was first disclosed in October 2019. Although the company has not revealed its first pre-clinical candidate, it launched with $315M in combined Series A and B funding. The company is co-founded by Professor David R. Liu, who also co-founded Editas Medicine, Beam Therapeutics, Pairwise Plants and Exo Therapeutics.


HashtagPrime Medicine

Company: Prime Medicine
Search CRISPR Medicine